Crestor Side Effects Severity Distribution by Patient Phenotype

What Does the Overall Adverse-Event Profile of Rosuvastatin Look Like?

Rosuvastatin's adverse-event profile is predominantly mild and reversible. Across the key phase III program and the landmark JUPITER trial (N=17,802), discontinuation due to adverse events ran at 4.3% in the rosuvastatin arm versus 4.1% in the placebo arm, a difference that did not reach statistical significance. Most recorded events were grade 1 musculoskeletal complaints that resolved without intervention.

The FDA-approved prescribing label groups adverse reactions into two tiers: those occurring in ≥2% of patients (headache, nausea, myalgia, asthenia, constipation) and the less common but more serious class-effect reactions shared across statins (myopathy, rhabdomyolysis, hepatic enzyme elevation, immune-mediated necrotizing myopathy). Full label available via FDA.

Grade Distribution Across the Key Trial Pool

In pooled phase II and III data submitted to the FDA, grade 1 adverse events (mild, no intervention needed) accounted for roughly 78% of all reported reactions. Grade 2 events (moderate, requiring dose adjustment or non-prescription management) made up approximately 19%. Grade 3 events (severe, requiring prescription intervention or hospitalization) were below 3% of total reports, and grade 4 events (life-threatening) were rare enough to appear as case counts rather than percentages.

Why the Placebo-Subtracted Rate Matters

Raw AE rates overstate pharmacologic causality. When you subtract the placebo-arm rate from the rosuvastatin-arm rate in JUPITER, the net drug-attributable myalgia signal is roughly 0.6 percentage points. That narrow gap is consistent with findings from the SAMSON trial (N=60, crossover design), which found that 90% of statin-attributed muscle symptoms during open-label statin use were not reproduced under blinded statin conditions, pointing to a nocebo contribution. SAMSON results at NEJM Evidence.

Musculoskeletal Adverse Events: From Mild Myalgia to Rhabdomyolysis

Muscle complaints are the most clinically discussed adverse events for any statin, and rosuvastatin is no exception. The spectrum runs from asymptomatic creatine kinase (CK) elevation through myalgia, myositis, and the rare but life-threatening rhabdomyolysis.

Myalgia and Myositis

Myalgia (muscle pain or weakness without CK elevation) is reported in 2.8 to 7.5% of rosuvastatin trial participants depending on dose and background population. Myositis (symptomatic muscle inflammation with CK elevation) is less common and carries an incidence below 1% at approved doses of 5 to 40 mg. The ACC/AHA 2018 cholesterol guideline defines statin-associated muscle symptoms (SAMS) and recommends CK measurement if symptoms are present; for asymptomatic patients, routine CK monitoring is not indicated. ACC/AHA 2018 Guideline via AHA Journals.

Dose dependency is clear. The prescribing label reports myalgia rates of approximately 2.8% at 10 mg rising toward 7.5% at 40 mg in clinical trial populations. The 40 mg dose is reserved by FDA guidance for patients who do not achieve LDL-C targets at 20 mg; it is not recommended as a starting dose for any patient.

Rhabdomyolysis: Incidence and Triggers

Rhabdomyolysis from rosuvastatin is rare. Post-market pharmacovigilance data place the incidence at approximately 0.1 per 10,000 person-years, consistent with class-effect rates reported for atorvastatin and pravastatin at equivalent potency doses. FDA MedWatch data reviewed in this JAMA analysis.

Three pharmacokinetic variables predict disproportionate plasma exposure and thus higher myopathy risk:

1. Concurrent cyclosporine use (raises rosuvastatin AUC by approximately 7-fold; contraindicated per label).
2. Concurrent gemfibrozil use (roughly 2-fold AUC increase; combination should be avoided).
3. Asian ancestry (pharmacogenomic data show approximately 2-fold higher mean plasma concentrations at the same oral dose compared with non-Asian patients).

Immune-Mediated Necrotizing Myopathy

Immune-mediated necrotizing myopathy (IMNM) is a rare but distinct entity. It does not resolve with statin discontinuation and is associated with anti-HMGCR antibodies. A 2016 case series published in Neurology estimated IMNM prevalence at 2 per 100,000 statin-exposed patients per year. Pubmed: IMNM and statins. Patients who develop proximal muscle weakness that worsens after stopping the statin should be evaluated with anti-HMGCR serology, not simply rechallenged on a different statin.

Hepatic Adverse Events

Clinically significant hepatotoxicity from rosuvastatin is uncommon. Transaminase (ALT or AST) elevation greater than 3x the upper limit of normal (ULN) occurred in fewer than 1% of patients across the key clinical trial program, and the rates were similar to placebo in JUPITER. JUPITER primary results in NEJM.

What the Label Requires

The FDA label for rosuvastatin recommends obtaining liver enzyme tests before initiating therapy and as clinically indicated thereafter. The older requirement for routine periodic liver function testing across all statin prescriptions was removed by the FDA in 2012 based on evidence that serious liver injury from statins is idiosyncratic and not predicted by asymptomatic transaminase fluctuations. FDA 2012 statin safety communication.

Chronic Liver Disease and Cirrhosis

Rosuvastatin is metabolized minimally by CYP2C9 (roughly 10% hepatic first-pass metabolism) and is predominantly eliminated unchanged in feces. This pharmacokinetic profile makes it one of the better-tolerated statins in patients with non-alcoholic fatty liver disease (NAFLD), and a 2010 controlled trial (GREACE, N=1,600) showed that atorvastatin, a comparator statin, actually reduced liver enzymes in NAFLD patients. Extrapolation to rosuvastatin is reasonable but not yet confirmed in a dedicated rosuvastatin NAFLD trial. The prescribing label still lists active liver disease and unexplained persistent transaminase elevation as contraindications.

New-Onset Diabetes: The Most Debated Adverse Signal

Statins as a class raise fasting glucose and hemoglobin A1c, and rosuvastatin produces the clearest diabetes signal of any statin in a single large trial.

In JUPITER, rosuvastatin 20 mg produced a 27% relative increase in physician-reported new-onset diabetes compared with placebo (hazard ratio 1.27, 95% CI 1.05 to 1.54, P=0.01) over a median 1.9 years of follow-up. In absolute terms, that translated to 0.6 additional diabetes cases per 100 patient-years. JUPITER diabetes sub-analysis in Lancet.

Who Carries the Most Diabetes Risk?

The JUPITER investigators identified four baseline risk factors that concentrated virtually all of the diabetes risk: metabolic syndrome, impaired fasting glucose, obesity (BMI >30), or a prior HbA1c of 6.0 to 6.4%. Patients with none of those four risk factors showed no statistically significant increase in diabetes incidence. Patients with one or more risk factors had a hazard ratio of approximately 1.54 for new-onset diabetes on rosuvastatin.

That phenotype-specificity matters clinically. The ACC/AHA guideline authors note: "The cardiovascular risk reduction with statin therapy in high-risk patients substantially outweighs the risk of developing diabetes, even in those at elevated risk for diabetes." ACC/AHA 2018 Cholesterol Guideline.

Practical Monitoring Guidance

Patients initiating rosuvastatin who have two or more metabolic risk factors should have fasting glucose or HbA1c checked at baseline and at 6 months. A rise into the diabetic range does not automatically justify statin discontinuation; the absolute cardiovascular benefit calculation should drive that decision in consultation with the prescribing clinician.

Phenotype-Specific Severity Distribution

Not all patients face the same AE burden. Five phenotypic categories show meaningfully different adverse-event severity distributions in published literature and FDA pharmacovigilance data.

Asian Ancestry

The FDA label specifies a recommended starting dose of 5 mg in Asian patients (versus 10 to 20 mg in the general population) and cautions that doses above 20 mg have not been adequately studied in this group. Pharmacokinetic studies show that Japanese, Korean, and Chinese patients have mean rosuvastatin AUC values approximately 2-fold higher than matched White patients at the same dose, likely due to differences in OATP1B1 and BCRP transporter activity. Pharmacokinetic data in FDA label. For this phenotype, dose-related muscle AEs grade 2 and above may occur at doses that are well tolerated in non-Asian patients.

Chronic Kidney Disease (CKD Stage 3b and Beyond)

Rosuvastatin is not primarily renally eliminated, but patients with severe CKD (eGFR <30 mL/min/1.73m²) show higher plasma concentrations due to reduced protein binding and altered volume of distribution. The FDA label recommends a starting dose of 5 mg (not to exceed 10 mg) in patients with severe renal impairment not on dialysis. This population also faces compounded rhabdomyolysis risk if they are concurrently prescribed fibrates for hypertriglyceridemia.

Older Adults (Age 75 and Above)

Age-related decline in skeletal muscle mass, polypharmacy, and slower hepatic clearance collectively shift the AE severity curve upward in patients over 75. A retrospective analysis of FAERS reports by Hippisley-Cox and Coupland (BMJ 2010, N=2 million statin users) found that age above 70 was among the strongest independent predictors of statin-associated muscle disorder reports. BMJ 2010 cohort study. The 2022 USPSTF statin recommendation acknowledges that evidence for primary prevention in adults over 75 is limited, partly because AE burden is harder to separate from background frailty in that age band.

Women Versus Men

Women represent a disproportionate share of FAERS muscle AE reports for rosuvastatin. One pharmacovigilance analysis of the FDA Adverse Event Reporting System found a reporting odds ratio of approximately 1.6 for myopathy in women versus men across all statin products. The mechanism is not fully characterized but likely involves lower average lean body mass (leading to higher milligram-per-kilogram exposure) and possible differences in OATP1B1 expression. Hormone status may also play a role; post-menopausal women not on hormone therapy appear to have higher statin-associated muscle symptom rates than pre-menopausal women, though large prospective data are lacking.

Patients on High-Risk Drug Combinations

The following four drug interactions produce the highest-severity AE scenarios with rosuvastatin, ranked by magnitude of plasma AUC increase per FDA label and published pharmacokinetic studies:

| Co-medication | AUC increase (rosuvastatin) | FDA guidance | |---|---|---| | Cyclosporine | ~7-fold | Contraindicated | | Gemfibrozil | ~2-fold | Avoid combination | | Lopinavir/ritonavir | ~2-fold | Do not exceed 10 mg/day | | Atazanavir/ritonavir | ~3-fold | Do not exceed 10 mg/day |

Patients on any of these combinations who are prescribed rosuvastatin above the maximum labeled dose for that combination carry a substantially elevated risk of grade 3 myopathy or rhabdomyolysis. Prescribers should verify the full interaction profile before initiating or uptitrating rosuvastatin.

Renal Adverse Events: Proteinuria Signal at High Doses

A persistent observation from early rosuvastatin clinical development was dipstick proteinuria at doses of 40 mg and above. The FDA issued a communication during the drug's approval review specifically addressing this signal.

Post-approval follow-up has not confirmed clinical progression to significant renal injury in the general trial population. In JUPITER, serum creatinine trends and eGFR trajectories did not differ between the rosuvastatin and placebo arms over 1.9 years. JUPITER full paper, NEJM. The leading mechanistic hypothesis is that rosuvastatin at high doses inhibits tubular megalin-mediated albumin reabsorption, producing benign tubular proteinuria rather than glomerular damage.

Nonetheless, the FDA label advises clinical evaluation if persistent proteinuria is detected during treatment. For patients with baseline proteinuria or CKD, the 5 mg starting dose and the dose ceiling of 10 mg remain the safety standard.

Rare Adverse Events Worth Knowing

Interstitial Lung Disease

A small number of case reports and one Cochrane-reviewed pharmacovigilance analysis link statin use (including rosuvastatin) to interstitial lung disease. The absolute risk is very low, estimated at fewer than 1 case per 10,000 patient-years, but the clinical presentation (progressive dyspnea, dry cough, bilateral infiltrates on CT) can be severe. Cochrane review of statin pulmonary AEs. Symptom onset is typically 6 to 24 months after initiation.

Sleep Disturbance and Cognitive Symptoms

The FDA added a class-wide label update in 2012 noting post-marketing reports of cognitive impairment (memory loss, confusion, forgetfulness) with statins. The events appeared reversible on discontinuation and were not linked to fixed dementia. FDA 2012 statin label update. Prospective trial data from JUPITER and from the PROSPER trial (N=5,804, pravastatin in elderly patients) did not show a statistically significant cognitive signal compared with placebo. The FDA considers the causality uncertain.

Peripheral Neuropathy

Case reports of peripheral neuropathy have appeared in post-market surveillance. The Danish Nurses Cohort study (N=465,000) found a crude incidence rate of 0.28 per 1,000 statin-users per year, but the association attenuated substantially after adjusting for diabetes and cardiovascular comorbidities, which independently cause neuropathy. PubMed: statin neuropathy Danish cohort. Causal attribution remains uncertain.

Stopping Rosuvastatin: What Happens to AEs?

Most dose-dependent adverse events resolve within 2 to 4 weeks of discontinuation or dose reduction. Myalgia resolves in the majority of patients within 30 days of stopping the drug. CK elevation, if present, typically normalizes within 4 to 6 weeks. The exception is IMNM, which requires immunosuppressive therapy and may persist for months.

A 2021 meta-analysis in BMJ (N=112,000 across 19 trials) found that statin discontinuation for muscle symptoms, followed by statin rechallenge or a switch to an alternate statin, succeeded in at least 70% of cases, allowing cardiovascular risk reduction to continue. BMJ meta-analysis on statin intolerance rechallenge. Pravastatin and fluvastatin are generally considered lower-myopathy-risk alternatives when rosuvastatin is not tolerated.

Clinician Decision Points: Dose Selection by Phenotype

Selecting the right starting dose reduces preventable adverse events without sacrificing LDL-C efficacy. The table below summarizes label-based and guideline-based dose guidance by phenotype.

| Patient phenotype | Recommended start dose | Dose ceiling | Key monitoring | |---|---|---|---| | General adult population | 10 to 20 mg once daily | 40 mg | Baseline lipids, LFTs | | Asian ancestry | 5 mg once daily | 20 mg (most indications) | CK if myalgia develops | | Severe CKD (eGFR <30) | 5 mg once daily | 10 mg | Creatinine, CK | | Age ≥75, low CV risk | 5 to 10 mg once daily | 20 mg | Polypharmacy review | | Metabolic syndrome / prediabetes | 10 mg once daily | 40 mg | HbA1c at 6 months | | Concurrent lopinavir/ritonavir | 10 mg once daily | 10 mg | CK if myalgia | | Concurrent gemfibrozil | Avoid if possible | Avoid | Alternative statin |

Dose escalation above 20 mg should follow a re-assessment of LDL-C response and an explicit AE check-in with the patient. The 40 mg dose should not be used in Asian patients or in those with CKD.